United Therapeutics Corporation (NASDAQ:UTHR) has been given a consensus rating of “Hold” by the sixteen research firms that are presently covering the company, MarketBeat.com reports. Six investment analysts have rated the stock with a sell rating, seven have issued a hold rating and three have issued a buy rating on the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $127.80.
Several equities research analysts recently issued reports on the stock. BidaskClub downgraded shares of United Therapeutics Corporation from a “buy” rating to a “hold” rating in a research note on Wednesday, July 19th. HC Wainwright reissued a “hold” rating and issued a $95.00 target price on shares of United Therapeutics Corporation in a research report on Monday, April 17th. Jefferies Group LLC reissued a “sell” rating and issued a $116.00 target price on shares of United Therapeutics Corporation in a research report on Wednesday, April 12th. Wedbush reissued an “outperform” rating and issued a $213.00 target price (down previously from $229.00) on shares of United Therapeutics Corporation in a research report on Thursday, April 27th. Finally, Cowen and Company reissued a “hold” rating and issued a $121.00 target price on shares of United Therapeutics Corporation in a research report on Wednesday, April 26th.
In related news, Director Christopher Causey sold 590 shares of the stock in a transaction that occurred on Thursday, July 6th. The shares were sold at an average price of $132.61, for a total transaction of $78,239.90. Following the completion of the sale, the director now directly owns 3,875 shares of the company’s stock, valued at $513,863.75. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Raymond Dwek sold 3,490 shares of the business’s stock in a transaction that occurred on Friday, June 23rd. The shares were sold at an average price of $131.71, for a total transaction of $459,667.90. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 22,499 shares of company stock valued at $2,905,101. Company insiders own 7.80% of the company’s stock.
A number of hedge funds have recently bought and sold shares of the company. Ladenburg Thalmann Financial Services Inc. increased its stake in United Therapeutics Corporation by 11.3% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 717 shares of the biotechnology company’s stock valued at $104,000 after buying an additional 73 shares in the last quarter. Focused Wealth Management Inc increased its stake in United Therapeutics Corporation by 17.5% in the first quarter. Focused Wealth Management Inc now owns 940 shares of the biotechnology company’s stock valued at $127,000 after buying an additional 140 shares in the last quarter. Advisory Services Network LLC acquired a new stake in United Therapeutics Corporation during the first quarter valued at approximately $147,000. Daiwa Securities Group Inc. increased its stake in United Therapeutics Corporation by 17.4% in the first quarter. Daiwa Securities Group Inc. now owns 1,350 shares of the biotechnology company’s stock valued at $183,000 after buying an additional 200 shares in the last quarter. Finally, Campbell & CO Investment Adviser LLC acquired a new stake in United Therapeutics Corporation during the first quarter valued at approximately $204,000.
United Therapeutics Corporation (NASDAQ:UTHR) traded down 1.56% during mid-day trading on Friday, hitting $127.02. The stock had a trading volume of 711,228 shares. The company has a market cap of $5.52 billion, a price-to-earnings ratio of 14.73 and a beta of 1.51. The company has a 50 day moving average price of $130.84 and a 200-day moving average price of $135.59. United Therapeutics Corporation has a one year low of $110.90 and a one year high of $169.89.
United Therapeutics Corporation (NASDAQ:UTHR) last released its quarterly earnings results on Thursday, July 27th. The biotechnology company reported ($1.25) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $3.61 by $4.86. United Therapeutics Corporation had a return on equity of 20.96% and a net margin of 24.18%. The firm had revenue of $444.60 million for the quarter, compared to analysts’ expectations of $391.53 million. During the same period last year, the firm earned $4.42 EPS. The business’s quarterly revenue was up 7.8% on a year-over-year basis. Equities analysts expect that United Therapeutics Corporation will post $13.33 earnings per share for the current fiscal year.
United Therapeutics Corporation announced that its Board of Directors has authorized a share repurchase program on Thursday, April 27th that authorizes the company to repurchase $250.00 million in shares. This repurchase authorization authorizes the biotechnology company to repurchase up to 4.6% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company’s management believes its stock is undervalued.
United Therapeutics Corporation Company Profile
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).
Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.
